Carlyle Group Inc.
For the period ended Mar 31, 2025. Filed May 9, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 9, 2025
CG$41.70-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net income | $158.6 | $98.8 |
| Adjustments to reconcile net income to net cash flows from operating activities: | ||
| Depreciation and amortization | 46.9 | 45.3 |
| Equity-based compensation | 103.5 | 108.3 |
| Non-cash performance allocations and incentive fees, net | 15.0 | 190.9 |
| Non-cash principal investment income | 72.7 | (70.0) |
| Other non-cash amounts | 12.6 | (2.9) |
| Consolidated Funds related: | ||
| Realized/unrealized (gain) loss on investments of Consolidated Funds | (7.0) | (82.7) |
| Realized/unrealized (gain) loss from loans payable of Consolidated Funds | 0.9 | 89.7 |
| Purchases of investments by Consolidated Funds | (2,425.5) | (1,477.3) |
| Proceeds from sales and settlements of investments by Consolidated Funds | 1,430.8 | 1,276.3 |
| Non-cash interest income, net | (4.1) | (6.7) |
| Change in cash and cash equivalents held at Consolidated Funds | 270.9 | (80.0) |
| Change in other receivables held at Consolidated Funds | 8.3 | (65.0) |
| Change in other liabilities held at Consolidated Funds | (2.5) | 227.9 |
| Purchases of investments | (78.3) | (145.1) |
| Proceeds from the sale of investments | 144.8 | 102.1 |
| Payments of contingent consideration | (1.0) | (1.5) |
| Changes in deferred taxes, net | (29.4) | (47.1) |
| Change in due from affiliates and other receivables | 10.7 | 6.7 |
| Change in deposits and other | (10.8) | (19.7) |
| Change in accounts payable, accrued expenses and other liabilities | (25.4) | 41.5 |
| Change in accrued compensation and benefits | (327.7) | (365.6) |
| Change in due to affiliates | 6.5 | (2.2) |
| Change in lease right-of-use assets and lease liabilities | (2.8) | (2.2) |
| Change in deferred revenue | 280.2 | 251.6 |
| Net cash (used in) provided by operating activities | (352.1) | 71.1 |
| Cash flows from investing activities | ||
| Purchases of fixed assets, net | (16.7) | (14.2) |
| Net cash used in investing activities | (16.7) | (14.2) |
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from financing activities | ||
| Payments on CLO borrowings | (14.6) | (13.9) |
| Proceeds from CLO borrowings, net of financing costs | 15.1 | — |
| Net borrowings on loans payable of Consolidated Funds | 559.4 | 45.3 |
| Dividends to common stockholders | (126.4) | (126.7) |
| Payment of deferred consideration for Carlyle Holdings units | — | (68.8) |
| Contributions from non-controlling interest holders | 163.0 | 64.7 |
| Distributions to non-controlling interest holders | (164.2) | (19.0) |
| Common shares repurchased and net share settlement of equity-based awards | (176.5) | (150.0) |
| Change in due to/from affiliates financing activities | 40.8 | 51.7 |
| Net cash provided by (used in) financing activities | 296.6 | (216.7) |
| Effect of foreign exchange rate changes | 5.0 | (4.4) |
| Decrease in cash, cash equivalents and restricted cash | (67.2) | (164.2) |
| Cash, cash equivalents and restricted cash, beginning of period | 1,266.5 | 1,442.1 |
| Cash, cash equivalents and restricted cash, end of period | $1,199.3 | $1,277.9 |
| Supplemental non-cash disclosures | ||
| Initial consolidation of Consolidated Funds | $57.0 | $— |
| Reconciliation of cash, cash equivalents and restricted cash, end of period: | ||
| Cash and cash equivalents | $1,190.3 | $1,276.5 |
| Restricted cash | 9.0 | 1.4 |
| Total cash, cash equivalents and restricted cash, end of period | $1,199.3 | $1,277.9 |
| Cash and cash equivalents held at Consolidated Funds | $570.9 | $426.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.